Hailed as a major scientific advance when they were introduced in the mid-1970s, monoclonal antibodies (mAbs) were slow to be applied outside of the lab. COVID-19 has changed everything.
A rapid development of new and diverse medical indications for mAbs is underway. RGA's Dr. Daniel D. Zimmerman, Senior Vice President, Head of Global Medical, reviews the clinical indications of monoclonal antibodies, and examines the potential impact of this fast-growing class of therapeutics on insurance medicine. mAbs are also playing an emerging role in the treatment of COVID-19, and this will be addressed.
See also: The Monoclonal Antibody Revolution – What Insurers Need to Know
At RGA, we are eager to engage with clients to better understand and tackle the industry’s most pressing challenges together. Contact us to discuss and learn more about the RGA capabilities, resources, and solutions.